跳至主要内容
临床试验/NCT00334945
NCT00334945已完成不适用

Evaluate the Effect of Growth Hormone (GH) Treatment on Fibroblast Growth Factor 23 (a Known Phosphaturic Agent)

University of Alabama at Birmingham0 个研究点目标入组 35 人开始时间: 2006年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
35

研究概览

简要总结

The purpose of this study is to evaluate the effect of growth hormone treatment on phosphorus levels in the body. Phosphorus is an important mineral for bone growth. It is well known that growth hormone treatment improves bone density and bone mineral content. The amount of phosphorus is maintained by the kidneys. Fibroblast Growth Factor 23 has recently been recognized to help kidneys control phosphate levels.

详细描述

This study will compare Fibroblast Growth Factor 23 levels in children with and without growth hormone deficiency. Children with growth hormone deficiency will have levels taken before starting growth hormone replacement and after it has been initiated.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
3 Years 至 14 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Twenty children with significant short stature < 3rd percentile, ages 3-14 years, and referred to Children's Hospital of Alabama
  • Normal healthy volunteer children 3-18 years with normal stature

排除标准

  • Patients on medication including GH
  • Patients with concomitant hormonal abnormalities
  • Patients with disorders of calcium and phosphate metabolism
  • Active neoplasms
  • Closed epiphysis
  • Known bone disorders

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ambika Ashraf, M.D.

Principal Investigator

University of Alabama at Birmingham

相似试验

Evaluate the Effect of Growth Hormone (GH) Treatment... | 临床试验